Key Highlights
- Loss per share was USD 0.20, against an estimate of a USD 0.14 loss.
- Government contract Revenue was USD 105 thousand for the quarter.
- Net loss was USD 3.44 million, against USD 2.05 million a year earlier.
- Cash was USD 4.87 million at September 30, 2026.
Cocrystal Pharma (NASDAQ:COCP) lost USD 3.44 million in the third quarter of 2026, against USD 2.05 million in the prior-year quarter. The basic and diluted net loss per common share was USD 0.20, against USD 0.19 a year earlier and an estimated loss of USD 0.14.
The company recognized government contract revenue of USD 105 thousand for the quarter and USD 435 thousand for the nine months ended September 30, 2026. The filing says the contract is with NIAID, which is the customer for Research and Development services.
Spending and Other Income
Research and development expenses rose to USD 1.98 million from USD 954 thousand, and general and administrative expenses rose to USD 1.62 million from USD 1.14 million. Total operating expenses were USD 3.59 million, against USD 2.09 million, and the loss from operations was USD 3.49 million, against USD 2.09 million.
Total other income, net, was USD 45 thousand, against USD 40 thousand, made up of net interest income of USD 15 thousand and a foreign exchange gain of USD 30 thousand. Weighted average shares outstanding were 17,419 thousand, against 10,991 thousand.
Nine Months at a Glance
For the nine months, research and development expenses were USD 5.49 million, against USD 3.44 million, and general and administrative expenses were USD 3.97 million, against USD 3.10 million. Total operating expenses were USD 9.46 million, against USD 6.54 million. The loss from operations was USD 9.03 million, against USD 6.54 million, and the net loss was USD 8.91 million, against USD 6.41 million. The net loss per common share was USD 0.59, against USD 0.61.
Cash, Financing and the Antiviral Pipeline
Cash was USD 4.87 million at September 30, 2026, against USD 7.03 million at December 31, 2025, and restricted cash was USD 75 thousand. A government contract receivable of USD 35 thousand was recorded at September 30, 2026.
The company says its current resources are not enough to fund operations for at least 12 months from the date the financial statements are issued. It sold and issued 5,474,053 shares of common stock to an Accredited Investor at USD 0.9134 per share, for gross proceeds of USD 5.0 million. About 19,264,893 shares were outstanding as of November 16, 2026.
The company has identified preclinical and clinical-stage antiviral compounds for unmet medical needs caused by RNA viruses, including norovirus, influenza virus, coronaviruses and hepatitis C virus. Over the nine months, its research and development efforts focused mainly on norovirus, influenza and coronavirus. It engaged hVIVO Services, a United Kingdom clinical research organization, to run its Phase 2a human challenge study of oral CC-42344.
The Quarter in Brief
Cocrystal Pharma reported a third quarter 2026 net loss of USD 3.44 million and a loss of USD 0.20 per share. Cash was USD 4.87 million at September 30, 2026.






Please wait processing your request...